Ipsen announced that NICE has recommended elafibranor for the treatment of PBC on the NHS. PBC is a rare liver disease that can lead to liver failure. Elafibranor is the first medicine for PBC approved in nearly a decade and will be funded through the Innovative Medicines Fund until final approval. Research shows the significant impact of PBC on patient’s quality of life. Elafibranor has shown positive results in clinical trials, with improvements in liver function and itch intensity. The availability of this new treatment option is seen as a significant step forward for PBC patients in the UK.
Source link
Ipsen’s elafibranor recommended for use in patients with rare liver disease
